⚠️Something went wrong...

We noticed you checked out the event page, but didn’t sign up. We noticed you checked out the event page, but didn’t sign up. Hotlist Follow Up Hey, Keith Kohl is about to reveal the trading strategy that’s been helping him grab double and triple-digit gains off of biotech… Up to 3 times each week! If you want the chance to make serious money in 2021, this strategy could be the best way to do it. We noticed you checked out the event page, but didn’t sign up. We want to make sure you don’t miss this one-time event. So, [click here now to lock in your seat.]( And remember, on Thursday, May 20 at 3PM… You’ll learn the exact strategy that’s been helping Keith find winners like 225% on Intra-Cellular Therapies… 77% on Evoke Pharma… And 171% on Aurinia Pharmaceuticals… Up to 3 times each week! You owe it to yourself to at least check this out. So, [click here now to register.]( Sincerely, [dave-roberts-signature] Dave Roberts Senior Executive, Angel Publishing --------------------------------------------------------------- If you no longer wish to receive updates from Catalyst Calendar you [may opt out here.]( Catalyst Calendar, Copyright © 2021, Angel Publishing, LLC., 3 E. Read Street, Baltimore, MD 21202. For customer service, please call 877-303-4529. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Angel Publishing and Catalyst Calendar do not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors, and consultants of Angel Publishing may actively trade in the investments discussed in this newsletter. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by xerography, facsimile, or any other means is illegal and punishable by law.